

Request Information

Permalink

Novel Solid Tumor Chemodrug LLS2

Tech ID: 27246 / UC Case 2015-832-0

ABSTRACT

Researchers at the University of California, Davis have developed a new library of small molecule LLS2 that can kill a variety of cancer cells

FULL DESCRIPTION

Surgical treatment for solid malignancies are the gold standard for operable tumors. Advanced solid tumor cancers that cannot just be resected require sophisticated multimodality regimens. Current advanced solid tumor cancer treatments include the use of radiation treatment and chemotherapy. Radiation treatment plays an important role in the treatment of patients but is criticized for its failure to consider the biology of the disease. Chemotherapeutic agents are becoming increasingly important as possible treatments for cancer but are susceptible to cancer resistance and compensatory cancer pathways. Therefore, there is a need for new compounds that can specifically target tumors based on their biology while being able to work concurrently with existing cancer therapies.

Researchers at the University of California, Davis have developed a new library of small molecule compound LLS2 that can kill a variety of cancer cells. The molecule specifically targets Galectin-1, a protein involved in proliferation, apoptosis, cell cycle, and angiogenesis. High expression of galectin-1 has been directly implicated in the process of tumorigenesis and identified in many human cancers including: ovarian, prostate, lung, breast, kidney, and pancreatic. The small molecule LLS2 can be used in combination with available chemotherapy drugs, be delivered orally, synthesized cost-effectively in a relatively short period of time and easily screened for specificity and capacity of binding with a target. LLS2 provides a new cancer-specific therapeutic that can be used in combinatorial therapies for a range of cancers.

APPLICATIONS

- ▶ Combinatorial cancer therapies

FEATURES/BENEFITS

- ▶ Cancer Specific
- ▶ Concurrent treatment
- ▶ Quickly synthesized
- ▶ Easily screened
- ▶ Orally bioavailable
- ▶ Cost-effective manufacturing

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,844,052	11/24/2020	2015-832

CONTACT

Raj Gururajan
rgururajan@ucdavis.edu
tel: 530-754-7637.



INVENTORS

- ▶ Lam, Kit S.
- ▶ Liu, Ruiwu
- ▶ Shih, Tsung-Chieh

OTHER INFORMATION

KEYWORDS

Galectin-1, cancer, LLS2, cancer therapy, solid tumor

CATEGORIZED AS

- ▶ **Biotechnology**
 - ▶ Other
- ▶ **Medical**
 - ▶ Diagnostics
 - ▶ Disease: Cancer
 - ▶ New Chemical Entities, Drug Leads
 - ▶ Other
 - ▶ Research Tools
 - ▶ Therapeutics
- ▶ **Research Tools**
 - ▶ Cell Lines
 - ▶ Other
 - ▶ Screening Assays

RELATED CASES

2015-832-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
- ▶ Conjugates That Combine HDAC Inhibitors and Retinoids into Disease Preventatives/Treatments
- ▶ Artificial Intelligence-Based Evaluation Of Drug Efficacy

- ▶ A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
- ▶ Site-Specific Ligation and Compound Conjugation to Existing Antibodies
- ▶ Ligands for Alpha-4-Beta-1 Integrin
- ▶ Functional Illumination in Living Cells
- ▶ Multifunctional Porphyrin-Based Nanomedicine Platform
- ▶ Engineered Biomaterial to Prevent Endothelial Inflammation
- ▶ Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
- ▶ PVA Nanocarrier System for Controlled Drug Delivery

University of California, Davis

InnovationAccess

1850 Research Park Drive, Suite 100, ,
Davis, CA 95618

Tel: 530.754.8649

innovationAccess@ucdavis.edu

research.ucdavis.edu/u/s/ia

Fax: 530.754.7620

© 2016 - 2023, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)